AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1200 participants.

Also called NCT07931573

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,200 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07931573
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Saudi Arabia, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07931573. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-10 (anticipated); primary completion 2028-07-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
Acronym
AMBITION 3
Intervention (Drug)
Zenagamtide
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07931573
Content hash
cd5558c97ad2ba7918c5b2d5155aa34aa92e544055839a9e18bca6f5b44b9c44